Jamel Chelly

Jamel Chelly

Auto-generated profile, based on publicly available information

Jamel Chelly

Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
DSDeciphering Developmental Disorders study
Deciphering Developmental Disorders study
LBLoïc Broix
Loïc Broix
HJHélène Jagline
Hélène Jagline
EIEkaterina L Ivanova
Ekaterina L Ivanova
SSStéphane Schmucker
Stéphane Schmucker
JCJamel Chelly
Jamel Chelly
Jamel Chelly and colleagues identify mutations in the E3 ubiquitin ligase gene NEDD4L that cause a syndrome of periventricular nodular heterotopia associated with neurodevelopmental disorders, cleft palate and toe syndactyly. The authors show that the mutations affect the mTORC1 and AKT pathways and cause defects in mouse brain development. Neurodevelopmental disorders with periventricular nodular heterotopia (PNH) are etiologically heterogeneous, and their genetic causes remain in many cases unknown. Here we show that missense mutations in NEDD4L mapping to the HECT domain of the encoded E3 ubiquitin ligase lead to PNH associated with toe syndactyly, cleft palate and neurodevelopmental delay. Cellular and expression data showed sensitivity of PNH-associated mutants to proteasome degradation. Moreover, an in utero electroporation approach showed that PNH-related mutants and excess wild-type NEDD4L affect neurogenesis, neuronal positioning and terminal translocation. Further investigations, including rapamycin-based experiments, found differential deregulation of pathways involved. Excess wild-type NEDD4L leads to disruption of Dab1 and mTORC1 pathways, while PNH-related mutations are associated with deregulation of mTORC1 and AKT activities. Altogether, these data provide insights into the critical role of NEDD4L in the regulation of mTOR pathways and their contributions in cortical development.

1 September 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EIEkaterina L. Ivanova
Ekaterina L. Ivanova
FMFrédéric Tran Mau-Them
Frédéric Tran Mau-Them
SRSaima Riazuddin
Saima Riazuddin
KKKimia Kahrizi
Kimia Kahrizi
VLVincent Laugel
Vincent Laugel
JCJamel Chelly
Jamel Chelly

14 November 2015 in Skeletal Muscle
Verified
Journal Article
Open access
PDF file
EMEmmanuelle Massouridès
Emmanuelle Massouridès
JPJérôme Polentes
Jérôme Polentes
PMPhilippe-Emmanuel Mangeot
Philippe-Emmanuel Mangeot
VMVirginie Mournetas
Virginie Mournetas
JNJuliette Nectoux
Juliette Nectoux
CPChristian Pinset
Christian Pinset
Duchenne muscular dystrophy (DMD) is a devastating X-linked recessive genetic myopathy. DMD physiopathology is still not fully understood and a prenatal onset is suspected but difficult to address. The bone morphogenetic protein 4 (BMP4) is a critical signaling molecule involved in mesoderm commitment. Human induced pluripotent stem cells (hiPSCs) from DMD and healthy individuals and human embryonic stem cells (hESCs) treated with BMP4 allowed us to model the early steps of myogenesis in normal and DMD contexts. Unexpectedly, 72h following BMP4 treatment, a new long DMD transcript was detected in all tested hiPSCs and hESCs, at levels similar to that found in adult skeletal muscle. This novel transcript named “Dp412e” has a specific untranslated first exon which is conserved only in a sub-group of anthropoids including human. The corresponding novel dystrophin protein of 412-kiloDalton (kDa), characterized by an N-terminal-truncated actin-binding domain, was detected in normal BMP4-treated hiPSCs/hESCs and in embryoid bodies. Finally, using a phosphorodiamidate morpholino oligomer (PMO) targeting the DMD exon 53, we demonstrated the feasibility of exon skipping validation with this BMP4-inducible hiPSCs model. In this study, the use of hiPSCs to analyze early phases of human development in normal and DMD contexts has led to the discovery of an embryonic 412 kDa dystrophin isoform. Deciphering the regulation process(es) and the function(s) associated to this new isoform can contribute to a better understanding of the DMD physiopathology and potential developmental defects. Moreover, the simple and robust BMP4-inducible model highlighted here, providing large amount of a long DMD transcript and the corresponding protein in only 3 days, is already well-adapted to high-throughput and high-content screening approaches. Therefore, availability of this powerful cell platform can accelerate the development, validation and improvement of DMD genetic therapies.

23 September 2015 in European Journal of Human Genetics
Verified
Journal Article
Closed access
JZJulia Lauer Zillhardt
Julia Lauer Zillhardt
KPKarine Poirier
Karine Poirier
LBLoïc Broix
Loïc Broix
NLNicolas Lebrun
Nicolas Lebrun
AEAdrienne Elmorjani
Adrienne Elmorjani
JCJamel Chelly
Jamel Chelly

12 March 2007 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ABArmand Bottani
Armand Bottani
JCJamel Chelly
Jamel Chelly
ABArjan P.M. de Brouwer
Arjan P.M. de Brouwer
BPBruno Pardo
Bruno Pardo
MBMandy Barker
Mandy Barker
BCBernard Conrad
Bernard Conrad

1 April 2016 in Revue Neurologique
Verified
Journal Article
Closed access
TWThomas Wirth
Thomas Wirth
MRMathilde Renaud
Mathilde Renaud
OBOuhaid Lagha Boukbiza
Ouhaid Lagha Boukbiza
GRGabrielle Rudolf
Gabrielle Rudolf
JCJamel Chelly
Jamel Chelly
MAMathieu Anheim
Mathieu Anheim